Patent · US Active

Antibody-fynomer conjugates

US10323095B2 · kind B2 · utility

1Cited by

2References

20Claims

0Family size

Assignee

MITSUBISHI TANABE PHARMA CORPORATION · JP

Inventors

Roland A. Newman · San Diego, US
Steve Granger · Encinitas, US
Michael Lyman · San Diego, US
Dragan Grabulovski · Zürich, CH
Richard Woods · Schlieren, CH
Michela Silacci · Zürich, CH
Wenjuan Zha · Singapore, SG
Isabella Attinger-Toller · Zürich, CH

Key dates

Filing date	Mar 16, 2015
Grant date	Jun 18, 2019
Priority date	—
Expiry date	Mar 16, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.